Nancy Pelosi and Donald Trump Are Meeting Today. Here's What They'll Discuss

Natasha Bach

Updated Wed, May 22, 2019, 11:04 AM

While the rest of the Democratic caucus seems to be focusing on impeachment, House Speaker Nancy Pelosi is heading to the White House to discuss the nation’s crumbling infrastructure with President Donald Trump.

Pelosi will be joined by Democratic Senate Minority Leader Chuck Schumer and other committee chairs to discuss how to pay for the bipartisan $2 trillion infrastructure plan initially unveiled in April.

Both Congressional Democrats and the administration agree that there is a need to address the vast array of infrastructure issues facing the U.S., but the discussion has a number of thorns in its side.

Ahead of Wednesday’s meeting, Trump sent a letter to Pelosi and Schumer Tuesday evening informing them that he felt it important to prioritize USMCA—the trade pact intended to replace the North American Free Trade Agreement (NAFTA) with Canada and Mexico—instead.

“Before we get to infrastructure, it is my strong view that Congress should first pass the important and popular USMCA trade deal,” Trump wrote. “Once Congress has passed USMCA, we should turn our attention to a bipartisan infrastructure package.”

He nevertheless appeared ready to discuss the infrastructure bill on Wednesday, writing that he remains “committed to passing an infrastructure bill.”

“It would be helpful if you came to tomorrow’s meeting with your infrastructure priorities and specifics regarding how much funding you would dedicate to each,” he continued. “Your caucus has expressed a wide range of priorities, and it is unclear which ones have your support.”

Pelosi and Schumer appeared to ignore his request in a statement they released ahead of the meeting.

“We look forward to hearing the President’s plan for how to pay for this package,” they wrote.

Last month, Pelosi and Schumer had announced that Trump had agreed to the $2 trillion price tag for their infrastructure plan, but would need to meet again to discuss how to pay for it. Following their initial meeting, Schumer noted that they had asked Trump for his ideas as to how to fund the bill. They expected Trump to present his proposal in this second meeting scheduled for Wednesday.

More must-read stories from Fortune

—Nike, Adidas slam tariffs in open letter to Trump

—Can Roe v. Wade be overturned?

—Breaking up Facebook is quickly becoming a 2020 campaign issue

—What’s behind the U.S. legal immigration slowdown?

—Listen to our new audio briefing, Fortune 500 Daily

Get up to speed on your morning commute with Fortune’s CEO Daily newsletter.

Here's Exactly When Social Security Recipients Can Expect Benefit Cuts, According to the Latest Trustees Report
Social Security payments may be subject to cuts. Here's what the timing looks like.
Motley Fool
Can I Use My RMDs to Transfer Money Into My Roth IRA?
If you're taking a required minimum distribution from an IRA, 401(k) or other tax-deferred account and don't need the money to cover living expenses, where should you stash that unneeded cash? Investors now need to start taking RMDs at age 73 or, if they were born after 1960, at age 75. Depending on the balances of […] The post Can I Use My RMDs to Transfer Money Into My Roth IRA? appeared first on SmartReads by SmartAsset.
SmartAsset
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor added to these three existing positions on Tuesday.
Motley Fool
How Much Cash Can A $300,000 Annuity Generate For Me Each Month?
Imagine having a reliable source of income you can count on throughout your retirement. That’s the promise of an annuity. These insurance products have been designed to turn your savings into a steady stream of monthly payments. They guarantee peace of mind and financial security in your golden years. Don't Miss: Are you rich? Here’s what Americans think you need to be considered wealthy. Can you guess how many Americans successfully retire with $1,000,000 saved? The percentage may shock you. An
Benzinga
Stocks could tank after an ill-advised 'melt-up' if the Fed cuts rates to avoid recession
"Investors' expectation that the Fed would nip a recession in the bud by easing means that the Fed Put is back," Ed Yardeni said.
Business Insider
Can You Guess What Percentage Of A High-Net-Worth Individual's Portfolio Is Typically Held In Retirement Accounts?
High net worth individuals (HNWIs) are those who have at least $1 million in easily convertible assets like cash, stocks, and bonds. They often manage significant wealth across diverse portfolios. As per Empower’s financial dashboard, retirement accounts such as 401(k) plans and IRAs comprise 55% of total wealth for many HNWIs. This is a stark contrast to the median household. Pew Research Center reports that these accounts typically represent only 27% of the net worth of households where at lea
Benzinga
3 Ridiculously Undervalued Stocks to Buy Hand Over Fist Right Now in May
Investing in cheap stocks brings unique risks because there is usually a reason the companies are undervalued.
Motley Fool
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
Investor's Business Daily
Morgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ Stocks
Uncertainty is the word of the day, in reference to the near-term economic future. Sentiment will hinge on the inflation numbers due out next week. March’s figure rose to 3.5%, and April’s job numbers showed a marked slowing in the labor market; that combination has stoked fears of stagflation. But – corporate earnings from Q1 are beating expectations, and the stock market has taken a turn for the better with the S&P 500 closing just below 5,200 yesterday. Economic strategists are still optimist
TipRanks
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Benzinga

More must-read stories from Fortune

Recommended Stories